PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
8 September 2014
|
| In: |
Journal of clinical oncology
Year: 2014, Volume: 32, Issue: 29, Pages: 3212-3222 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2014.55.7876 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1200/JCO.2014.55.7876
|
| Author Notes: | Sibylle Loibl, Gunter von Minckwitz, Andreas Schneeweiss, Stefan Paepke, Annika Lehmann, Mahdi Rezai,Dirk M. Zahm, Peter Sinn, Fariba Khandan, Holger Eidtmann, Karel Dohnal, Clemens Heinrichs, Jens Huober, Berit Pfitzner, Peter A. Fasching, Fabrice Andre, Judith L. Lindner, Christos Sotiriou, August Dykgers, Sanxing Guo, Stephan Gade, Valentina Nekljudova, Sherene Loi, Michael Untch, and Carsten Denkert |
| Item Description: | Gesehen am16.02.2016 |
|---|---|
| Physical Description: | Online Resource |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2014.55.7876 |